ARDELYX, INC. Operating Cash Flow
ARDELYX, INC. (ARDX) reported Operating Cash Flow of -$38.64 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- ARDELYX, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$6.40M.
- ARDELYX, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$32.24M.
- ARDELYX, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $20.95M, a 113.57% increase year-over-year.
- ARDELYX, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $365.00K, a 27.15% decline year-over-year.
- ARDELYX, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$42.48M.
- ARDELYX, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$44.81M.
- ARDELYX, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$89.72M.
- ARDELYX, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$70.04M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$6.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$38.64M 10-Q · filed 2026-08-06 | -$17.68M derived: sum of 3 quarters · filed 2026-08-06 | -$17.32M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$32.24M 10-Q · filed 2026-04-30 | -$11.29M derived: sum of 2 quarters · filed 2026-04-30 | -$10.92M derived: sum of 3 quarters · filed 2026-04-30 | -$36.26M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $20.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $21.32M derived: sum of 2 quarters · filed 2026-02-19 | -$4.03M derived: sum of 3 quarters · filed 2026-08-06 | -$42.48M 10-K · filed 2026-02-19 |
| 2025-09-30 | $365.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$24.98M derived: sum of 2 quarters · filed 2026-08-06 | -$63.43M 10-Q · filed 2025-10-30 | -$53.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$25.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$63.80M 10-Q · filed 2026-08-06 | -$53.99M derived: sum of 3 quarters · filed 2026-08-06 | -$53.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$38.46M 10-Q · filed 2026-04-30 | -$28.65M derived: sum of 2 quarters · filed 2026-04-30 | -$28.15M derived: sum of 3 quarters · filed 2026-04-30 | -$47.54M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $9.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $10.31M derived: sum of 2 quarters · filed 2026-02-19 | -$9.09M derived: sum of 3 quarters · filed 2026-02-19 | -$44.81M 10-K · filed 2026-02-19 |
| 2024-09-30 | $501.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$18.90M derived: sum of 2 quarters · filed 2025-10-30 | -$54.62M 10-Q · filed 2025-10-30 | -$63.34M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | -$19.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | -$55.12M 10-Q · filed 2025-08-04 | -$63.84M derived: sum of 3 quarters · filed 2026-02-19 | -$85.31M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | -$35.72M 10-Q · filed 2025-05-01 | -$44.44M derived: sum of 2 quarters · filed 2026-02-19 | -$65.91M derived: sum of 3 quarters · filed 2026-02-19 | -$80.64M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | -$8.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$30.18M derived: sum of 2 quarters · filed 2026-02-19 | -$44.92M derived: sum of 3 quarters · filed 2026-02-19 | -$89.72M 10-K · filed 2026-02-19 |
| 2023-09-30 | -$21.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$36.20M derived: sum of 2 quarters · filed 2024-10-31 | -$81.00M 10-Q · filed 2024-10-31 | -$66.72M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | -$14.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$59.53M 10-Q · filed 2024-08-01 | -$45.25M derived: sum of 3 quarters · filed 2025-02-20 | -$70.67M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | -$44.80M 10-Q · filed 2024-05-02 | -$30.51M derived: sum of 2 quarters · filed 2025-02-20 | -$55.94M derived: sum of 3 quarters · filed 2025-02-20 | -$87.22M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $14.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | -$11.14M derived: sum of 2 quarters · filed 2025-02-20 | -$42.42M derived: sum of 3 quarters · filed 2025-02-20 | -$70.04M 10-K · filed 2025-02-20 |
| 2022-09-30 | -$25.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | -$56.71M derived: sum of 2 quarters · filed 2023-10-31 | -$84.33M 10-Q · filed 2023-10-31 | -$123.80M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$31.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$58.90M 10-Q · filed 2023-08-02 | -$98.37M derived: sum of 3 quarters · filed 2024-02-22 | -$132.96M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$27.62M 10-Q · filed 2023-05-03 | -$67.09M derived: sum of 2 quarters · filed 2024-02-22 | -$101.68M derived: sum of 3 quarters · filed 2024-02-22 | -$135.95M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$39.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$74.06M derived: sum of 2 quarters · filed 2024-02-22 | -$108.33M derived: sum of 3 quarters · filed 2024-02-22 | -$152.55M 10-K · filed 2024-02-22 |
| 2021-09-30 | -$34.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$68.86M derived: sum of 2 quarters · filed 2022-11-03 | -$113.08M 10-Q · filed 2022-11-03 | -$130.67M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | -$34.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$78.49M 10-Q · filed 2022-08-04 | -$96.08M derived: sum of 3 quarters · filed 2023-03-02 | -$115.96M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | -$44.22M 10-Q · filed 2022-05-05 | -$61.81M derived: sum of 2 quarters · filed 2023-03-02 | -$81.68M derived: sum of 3 quarters · filed 2023-03-02 | -$100.71M derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | -$17.59M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | -$37.47M derived: sum of 2 quarters · filed 2023-03-02 | -$56.49M derived: sum of 3 quarters · filed 2023-03-02 | -$81.44M 10-K · filed 2023-03-02 |
| 2020-09-30 | -$19.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$38.90M derived: sum of 2 quarters · filed 2021-11-12 | -$63.84M 10-Q · filed 2021-11-12 | -$74.98M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$19.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | -$43.97M 10-Q · filed 2021-08-13 | -$55.10M derived: sum of 3 quarters · filed 2022-02-28 | -$75.72M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$24.95M 10-Q · filed 2021-05-06 | -$36.08M derived: sum of 2 quarters · filed 2022-02-28 | -$56.70M derived: sum of 3 quarters · filed 2022-02-28 | -$84.52M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$11.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$31.75M derived: sum of 2 quarters · filed 2022-02-28 | -$59.57M derived: sum of 3 quarters · filed 2022-02-28 | -$76.48M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$20.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$48.43M derived: sum of 2 quarters · filed 2020-11-05 | -$65.35M 10-Q · filed 2020-11-05 | -$83.78M derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-06-30 | -$27.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$44.73M 10-Q · filed 2020-08-06 | -$63.17M derived: sum of 3 quarters · filed 2021-03-08 | -$90.19M derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-03-31 | -$16.91M 10-Q · filed 2020-05-07 | -$35.35M derived: sum of 2 quarters · filed 2021-03-08 | -$62.37M derived: sum of 3 quarters · filed 2021-03-08 | -$80.38M derived: sum of 4 quarters · filed 2021-03-08 |
| 2018-12-31 | -$18.44M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | -$45.45M derived: sum of 2 quarters · filed 2021-03-08 | -$63.47M derived: sum of 3 quarters · filed 2021-03-08 | -$70.27M 10-K · filed 2021-03-08 |
| 2018-09-30 | -$27.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$45.03M derived: sum of 2 quarters · filed 2019-11-06 | -$51.84M 10-Q · filed 2019-11-06 | -$47.14M derived: sum of 4 quarters · filed 2020-03-06 |
| 2018-06-30 | -$18.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$24.82M 10-Q · filed 2019-08-09 | -$20.12M derived: sum of 3 quarters · filed 2020-03-06 | -$39.36M derived: sum of 4 quarters · filed 2020-03-06 |
| 2018-03-31 | -$6.80M 10-Q · filed 2019-05-07 | -$2.11M derived: sum of 2 quarters · filed 2020-03-06 | -$21.35M derived: sum of 3 quarters · filed 2020-03-06 | -$45.23M derived: sum of 4 quarters · filed 2020-03-06 |
| 2017-12-31 | $4.70M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-06 | -$14.54M derived: sum of 2 quarters · filed 2020-03-06 | -$38.43M derived: sum of 3 quarters · filed 2020-03-06 | -$65.19M 10-K · filed 2020-03-06 |
| 2017-09-30 | -$19.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$43.13M derived: sum of 2 quarters · filed 2018-11-07 | -$69.89M 10-Q · filed 2018-11-07 | |
| 2017-06-30 | -$23.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$50.65M 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | -$26.76M 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | -$92.53M 10-K · filed 2019-03-06 | |||
| 2015-12-31 | -$71.84M 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |